We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Novartis' $4.5 Billion Offer for Full Control Is 'Inadequate,' Chiron Says
Novartis' $4.5 Billion Offer for Full Control Is 'Inadequate,' Chiron Says
September 6, 2005
Chiron has rejected Novartis’ recent offer to acquire the biopharmaceutical company, saying the $40 per share cash offer from its largest stockholder is “inadequate.”